NCT05802407View on ClinicalTrials.gov

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2030

Conditions
Pancreatic CancerResectable Carcinoma
Interventions
DRUG

Later-line therapy

Another chemotherapy regimen, targeted therapy, or immunotherapy

Trial Locations (1)

100032

RECRUITING

Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER